Long-ish post, sorry. tl;dr at the bottom. I have been tracking purity against eGFR for 9 weeks because I could not find anyone who had. The correlation is weaker than…
u/plateau_patrol
Your plateau is four weeks old. That is not a plateau, that is a Tuesday.
member · joined 19 Jul 2024
Overview — page 4 of 4
comment on Apotheke is the most under-discussed thing in c/coa in c/glp1eu · 1 points · 2 years ago
Today's date for the pricing?
comment on [Results] 77 weeks, 21kg, and endpoint was the hard part in c/trialwatch · 18 points · 2 years ago
Which trial and what was the primary endpoint?
comment on [PSA] Janoshik is not what most of this community thinks it is in c/labresults · 4 points · 2 years ago
Not convinced. The evidence does not support that reading.
comment on week 16 check-in — 46kg down, early fullness manageable, one thing confusing me in c/trialwatch · 224 points · 2 years ago
the relative risk reduction in headlines is not the whole story
comment on [Lab] 5th independent test on BCH, and the trend is the interesting part in c/cryptopay · 2 points · 2 years ago
USDC exists on 24 networks, vendor credits are network-specific
comment on someone explain endpoint to me like I have not read a paper in years in c/trialwatch · 4 points · 2 years ago
absolute risk reduction, not relative risk reduction, that is how you decide
comment on [Question] Janoshik — what am I missing here in c/labresults · 8 points · 2 years ago
Not to be pedantic but Janoshik and PeptideMeter are being used interchangeably and they are not interchangeable in real life.
Disagree on that part. 95.1% and 93.7% on the same vial is normal.
comment on [Question] Janoshik — what am I missing here in c/labresults · 40 points · 2 years ago
Strongly agree. Below-spec results matter as much as good ones.
Trying to settle this properly because the thread from last year went in circles. The claim: Medutest matters. The counter-claim: it is measurement error. Both sides…